Diabetes und Fettleber

Norbert Stefan; Michael Roden

doi:10.1055/a-2076-0145

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2023; 18(S 02): S324-S329
DOI: 10.1055/a-2076-0145

DDG-Praxisempfehlung

Diabetes und Fettleber

Norbert Stefan

¹Deutsches Zentrum für Diabetesforschung (DZD), Deutschland

²Heisenberg-Professur und Lehrstuhl für klinisch-experimentelle Diabetologie, Abteilung für Innere Medizin IV, Bereiche Endokrinologie, Diabetologie und Nephrologie, Universitätsklinikum Tübingen, Deutschland

³Abteilung Pathophysiologie des Prädiabetes des Instituts für Diabetesforschung und Metabolische Erkrankungen (IDM) des Helmholtz Zentrums München an der Universität Tübingen, Deutschland

,

Michael Roden

¹Deutsches Zentrum für Diabetesforschung (DZD), Deutschland

⁴Klinik für Endokrinologie und Diabetologie, Medizinische Fakultät der Heinrich-Heine-Universität und Universitätsklinikum Düsseldorf, Deutschland

⁵Institut für Klinische Diabetologie, Deutsches Diabetes Zentrum (DDZ), Leibniz-Zentrum für Diabetesforschung an der Heinrich-Heine-Universität Düsseldorf, Deutschland

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol 2019; 70: 531-544
2 Eigentler T, Lomberg D, Machann J. et al. Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. Ann Intern Med 2020; 172: 836-837
3 Estes C, Anstee QM, Arias-Loste MT. et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018; 69: 896-904
4 Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7: 313-324
5 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
6 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
7 Roeb E, Canbay A, Bantel H. et al. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025. Z Gastroenterol 2022; 60: 1346-1421
8 European Association for the Study of the Liver (EASL); European European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140
9 European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021; 75: 659-689
10 Younossi ZM, Corey KE, Alkhouri N. et al. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther 2020; 52: 513-526
11 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42
12 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357
13 Bril F, McPhaul MJ, Caulfield MP. et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 2019; 67: 303-311
14 Eslam M, Sanyal AJ, George J. et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158: 1999-2014.e1
15 Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature 2019; 576: 51-60
16 Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol 2022; 10: 284-296
17 Younossi ZM, Rinella ME, Sanyal AJ. et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 2021; 73: 1194-1198
18 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1-9
19 Adams LA, Anstee QM, Tilg H. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153
20 Aminian A, Al-Kurd A, Wilson R. et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA 2021; 326: 2031-2042
21 Newsome PN, Buchholtz K, Cusi K. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021; 384: 1113-1124
22 Loomba R, Abdelmalek MF, Armstrong MJ. et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8: 511-522
23 Francque SM, Bedossa P, Ratziu V. et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med 2021; 385: 1547-1558
24 Harrison SA, Bashir MR, Guy CD. et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2019; 394: 2012-2024
25 Loomba R, Sanyal AJ, Kowdley KV. et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med 2023; 389: 998-1008